Skip to main content
Clinical Trials/NCT05209919
NCT05209919
Recruiting
Not Applicable

Echocardiographic Assessment and CLInical imPlication of Functional tricuSpid rEgurgitation in Heart Failure With Reduced or Preserved Ejection Fraction (ECLIPSE-HF)

Fondazione IRCCS Policlinico San Matteo di Pavia1 site in 1 country400 target enrollmentNovember 11, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Functional Tricuspid Regurgitation
Sponsor
Fondazione IRCCS Policlinico San Matteo di Pavia
Enrollment
400
Locations
1
Primary Endpoint
Time to all-cause death or to first HF hospitalization
Status
Recruiting
Last Updated
4 years ago

Overview

Brief Summary

Purpose Functional tricuspid regurgitation (FTR) has been shown to be associated with increased morbidity and mortality in several clinical conditions, including heart failure (HF) with reduced left ventricular ejection fraction as well as pulmonary arterial hypertension (PAH). We have designed a study aiming at: characterizing the echocardiographic morphology of the tricuspid valve apparatus and the pathophysiology of FTR in heart failure with reduced, mid-range or preserved left ventricular ejection fraction (HFrEF, HFmrEF, HFpEF) and in PAH patients; correlating the morphologic characteristics of tricuspid valve apparatus with hemodynamic severity of FTR; correlating the severity of FTR with the clinical condition and outcome. Methods The study will be a non-interventional, prospective, international, multicenter, longitudinal study. The minimum number of patients which are expected to be enrolled is 300 HF patients, including HFrEF, HFmrEF and HFpEF patients, whereas 100 PAH patients will serve as control. The patients will be enrolled in 20 centers in Europe, North America and Saudi Arabia. The echocardiographic parameters will be analyzed by the local investigators; a quality control committee will evaluate all data entered in the database to identify potential outliers and a random sample of 10% of cases will be blindly re-analysed in a central core-lab. Conclusions This study has been designed to improve our understanding of pathophysiological mechanisms and clinical relevance of FTR across all HF phenotypes. The results could potentially allow a more appropriate selection of heart failure patients with FTR for tricuspid valve intervention by percutaneous or surgical repair or replacement.

Registry
clinicaltrials.gov
Start Date
November 11, 2021
End Date
December 1, 2024
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Fondazione IRCCS Policlinico San Matteo di Pavia
Responsible Party
Principal Investigator
Principal Investigator

Stefano Ghio

MD

Fondazione IRCCS Policlinico San Matteo di Pavia

Eligibility Criteria

Inclusion Criteria

  • consecutive consenting outpatients with HFrEF, HFmrHF, HFpEF or PAH,
  • ambulatory visit routinely planned with an echocardiographic examination,
  • at the time of the visit at least moderate FTR diagnosed at echocardiography (by visual assessment),
  • aged ≥ 18 years old,
  • capable to sign an informed consent.

Exclusion Criteria

  • age \< 18 years old,
  • congenital heart disease,
  • heart failure due to organic mitral or aortic valve disease. No examination will be performed in addition to what is routinely planned for patients' evaluation.

Outcomes

Primary Outcomes

Time to all-cause death or to first HF hospitalization

Time Frame: 12 months

Study Sites (1)

Loading locations...

Similar Trials